Formulation and statistical optimization of intravenous Temozolomide loaded PEGylated liposomes to treat Glioblastoma Multiforme by three level factorial design.
Drug Dev Ind Pharm. 2017 Dec 27;:1-34
Authors: Vanza J, Jani P, Pandya N, Tandel H
Abstract
The aim of the presented study was to develop PEGylated liposomes of Temozolomide that provide optimum drug concentration at tumor site. Reverse phase evaporation (REV) method was used to prepare Temozolomide loaded PEGylated liposomes. Formulation was optimized by using design expert software by 32 factorial design. The physicochemical properties including size, morphology, entrapment efficiency, drug loading etc. of formulated liposomes were evaluated. Finally, the optimized formulation was selected for in vitro drug release and stability study. In vivo pharmacokinetic study in rats showed that Temozolomide loaded PEGylated liposomes leads to 1.6 fold increase in AUCTotal in blood and 4.2 fold increase in brain as compared to free drug solution. This formulated PEGylated liposomes offers a promising approach for treatment of Glioblastoma Multiforme.
PMID: 29280385 [PubMed - as supplied by publisher]
http://ift.tt/2pJCsp6
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου